Outlook Therapeutics Inc. — Expected to launch Lytenava (Bevacizumab Gamma) commercially in the EU in the first quarter of 2025
Outlook Therapeutics Inc——预计将于2025年第一季度在欧盟商业推出Lytenava（Bevacizumab Gamma）
Outlook Therapeutics Inc. — Expected to launch Lytenava (Bevacizumab Gamma) commercially in the EU in the first quarter of 2025
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.